Golli V, Tufescu R, Ciobanu C, Zaharia P, Bălaşa-Clotîrnoiu M
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol. 1978 Jan-Mar;23(1):37-42.
Primary resistance to tuberculostatics between 1971 and 1975 was studied in a lot of 676 adults with pulmonary tuberculosis, as well as the incidence and overall prevalence of primary and secondary resistance within the district covered by the tb. dispensary of Craiova. The incidence of primary resistance was of 13,61% of the entire lot, falling from 20.41% in 1971--1972, to 14.28% in 1973--1974 and to 7.25% in 1975. The incidence fell from 6.66 per 100 000 in 1971 to 2.3 per 100 000 in 1975, and the total prevalence of resistance from 27.7 per 100 000 in 1971 to 6.67 per 100 000 in 1975. Monoresistance was predominant (8.14% of the total), followed by biresistance (5.18%); primary triresistance was seldom recorded (0.29%). Biresistance rapidly decreased with years down to 1.55% in 1975 and triresistance disappeared in 1975. Although the frequency of primary resistance varies in terms of environment, sex and age of the patients, the differences are not statistically significant. Primary resistance to isoniazide and streptomycin occured in 7.99% of cases each, to ethambutol in 0.15% and to rifampicin in 0.51%. In order to reduce the cases of tuberculosis with primary resistance, endeavours should be directed towards the detection of all M. tuberculosis eliminators, applying a surveyed chemotherapy and following up the bacteriologic evolution of patients under specific treatment.
对676例成年肺结核患者在1971年至1975年期间的结核抑菌剂原发性耐药情况进行了研究,同时还研究了克拉约瓦结核病防治所辖区内原发性和继发性耐药的发生率及总体流行情况。原发性耐药发生率占全部病例的13.61%,从1971 - 1972年的20.41%降至1973 - 1974年的14.28%,再降至1975年的7.25%。发病率从1971年的每10万人6.66例降至1975年的每10万人2.3例,耐药总体流行率从1971年的每10万人27.7例降至1975年的每10万人6.67例。单耐药占主导(占总数的8.14%),其次是双耐药(5.18%);原发性三耐药很少见(0.29%)。双耐药随年份迅速下降,到1975年降至1.55%,三耐药在1975年消失。尽管原发性耐药的频率因患者的环境、性别和年龄而异,但差异无统计学意义。对异烟肼和链霉素的原发性耐药各占病例的7.99%,对乙胺丁醇的原发性耐药占0.15%,对利福平的原发性耐药占0.51%。为减少原发性耐药结核病病例,应努力发现所有结核分枝杆菌清除者,采用调查化疗并跟踪接受特定治疗患者的细菌学演变情况。